Gastrointestinal Disorders Therapeutics to 2016 Now Available at ReportsandReports
06/30/2010

GBI Research finds that the gastrointestinal disorder therapeutics market will decline during the period 2009-2016. It analyzes the markets for gastrointestinal disorder therapeutics in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan.

Online PR News – 30-June-2010 – – Dallas, TX: ReportsandReports announce it Will Gastrointestinal Disorders Therapeutics to 2016 – High Unmet Needs Triggering Strong Growth in Crohn's Disease and Irritable Bowel Syndrome Markets Market Research Report in its Store.

Browse complete Report on: http://www.reportsandreports.com/market-reports/gastrointestinal-disorders-therapeutics-to-2016-high-unmet-need/

GBI Research's report, “Gastrointestinal disorders therapeutics, analysis and forecasts to 2016 – high unmet needs triggering strong growth in crohn’s disease and irritable bowel syndrome markets”, provides in-depth analysis of the unmet needs, drivers and barriers that affect the global gastrointestinal disorder therapeutics market. It analyzes the markets for gastrointestinal disorder therapeutics in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales, price and volume are forecast until 2016 for the key geographies as well as the leading therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets. It is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.

GBI Research finds that the gastrointestinal disorder therapeutics market will decline during the period 2009-2016. This decline is primarily driven by the negative growth of gastroesophageal reflux disease (GERD) therapeutics market which is attributed to loss of drug patents and entry of generics. However, other key gastrointestinal disorders such as crohn’s disease and irritable bowels syndrome therapeutics market will continue to grow due to strong late stage pipeline that will address the unmet needs. The global gastrointestinal disorder therapeutics market is a highly fragmented market and big players are facing stiff competition. The forthcoming patent expiries of major drugs have increased the competition, driving the consolidation further. The increasing pressure has also driven companies to enter into licensing agreements. This allows companies to expand product portfolio and improve their competitive positions in the market.

Scope

The scope of this report includes:
- Annualized market data for the gastrointestinal disorder therapeutics market from 2001 to 2009, forecast forward to 2016
- Analysis of the leading therapeutic segments. These include crohn’s disease, ulcerative colitis, irritable bowel syndrome, and gastroesophageal reflux disease.
- Analysis of the gastrointestinal disorder therapeutics market in the leading geographies of the world, which include the US, the UK, Germany, France, Italy, Spain, and Japan
- Market characterization of the gastrointestinal disorder therapeutics market including market size, annual cost of therapy, and treatment usage patterns
- Key drivers and barriers that have a significant impact on the market
- Coverage of pipeline molecules in various phases of drug development
- Competitive benchmarking of leading companies. The key companies studied in this report are AstraZeneca, Takeda pharmaceutical company Ltd., Eisai pharmaceuticals Nycomed, Pfizer Inc, GlaxoSmithKline, Novartis AG, and Johnson & Johnson.
- Key M&A activities, licensing agreements, that have taken place between 2008 and 2009 in the global gastrointestinal disorder therapeutics market

Reasons to Buy

- The report will enhance your decision making capability. It will allow you to
- Align product portfolio to the markets with high growth potential
- Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth
- Reinforce R&D pipelines by identifying new target mechanisms which can produce first in class molecules with more efficiency and better safety
- Develop key strategic initiatives by understanding key focus areas of leading companies
- Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps

Table Of contents

1 Executive Summary 1

2 Table of Contents 3
2.1 List of Tables 8
2.2 List of Figures 11

3 Global Gastrointestinal Disorder Therapeutics Market: Scope of Research 13
3.1 Introduction 13
3.2 GBI Research Report Guidance 13

4 Global Gastrointestinal Disorder Therapeutics Market: Market Characterization 14
4.1 Market Forecasts 14
4.2 Annual Cost of Treatment 15
4.3 Usage Patterns 16
4.3.1 Diseased Population 16
4.3.2 Treatment Seeking Population 17
4.3.3 Diagnosis Population 18
4.3.4 Prescription Population 19
4.3.5 Threapy Usage Patterns 20
4.3.6 Geographical Distribution 21

5 Global Gastrointestinal Disorder Therapeutics Market: US Market 22
5.1 Market Overview 22
5.2 Market Forecasts 22
5.3 Annual Cost of Treatment 23
5.4 Usage Patterns 24
5.4.1 Diseased Population 24
5.4.2 Treatment Seeking Population 25
5.4.3 Diagnosis Population 26
5.4.4 Prescription Population 27
5.4.5 Threapy Usage Patterns 28

6 Global Gastrointestinal Disorder Therapeutics Market: European Market 30
6.1 Market Overview 30
6.2 Market Forecasts 30
6.3 Annual Cost of Treatment 31
6.4 Usage Patterns 32
6.4.1 Diseased Population 32
6.4.2 Treatment Seeking Population 33
6.4.3 Diagnosis Population 34
6.4.4 Prescription Population 35
6.4.5 Therapy Usage Patterns 36

7 Global Gastrointestinal Disorder Therapeutics Market : Japan Market 38
7.1 Market Overview 38
7.2 Market Forecasts 38
7.3 Annual Cost of Treatment 39
7.4 Usage Patterns 40
7.4.1 Diseased Population 40
7.4.2 Treatment Seeking Population 41
7.4.3 Diagnosis Population 42
7.4.4 Prescription Population 43
7.4.5 Therapy Usage Patterns 44

8 Global Irritable Bowel Syndrome Therapeutics Market 46
8.1 Market Overview 46
8.2 Market Forecasts 46
8.3 Annual Cost of Treatment 48
8.4 Usage Patterns 49
8.4.1 Diseased Population 49
8.4.2 Treatment Seeking Population 50
8.4.3 Diagnosis Population 51
8.4.4 Prescription Population 52
8.4.5 Threapy Usage Patterns 53
8.5 Product Analysis 54
8.5.1 Lotronex (Alosetron) 54
8.5.2 Amitiza (Lubiprostone) 55
8.5.3 Colpermin (Peppermint Oil) 55
8.5.4 Bentyl (Dicyclomine hydrochloride) 55
8.6 Drug Pipeline Analysis 56

9 Global Ulcerative Colitis Therapeutics Market 57
9.1 Market Overview 57
9.2 Market Forecasts 57
9.3 Annual Cost of Treatment 59
9.4 Usage Patterns 60
9.4.1 Diseased Population 60
9.4.2 Treatment Seeking Population 61
9.4.3 Diagnosis Population 62
9.4.4 Prescription Population 63
9.4.5 Threapy Usage Patterns 65
9.5 Product Analysis 66
9.5.1 Asacol 66
9.5.2 Lialda 66
9.5.3 Pentasa 66
9.5.4 Apriso 67
9.5.5 Colazal 67
9.5.6 Remicade 67
9.5.7 Azulfidine 67
9.6 Drug Pipeline Analysis 68

10 Global GERD Therapeutics Market 69
10.1 Market Overview 69
10.2 Market Forecasts 69
10.3 Annual Cost of Treatment 71
10.4 Usage Patterns 72
10.4.1 Diseased Population 72
10.4.2 Treatment Seeking Population 73
10.4.3 Diagnosis Population 74
10.4.4 Prescription Population 75
10.4.5 Threapy Usage Patterns 76
10.5 Product Analysis 77
10.5.1 Nexium (esomeprazole) 77
10.5.2 Aciphex (rabeprazole sodium) 77
10.5.3 Prevacid (lansoprazole) 77
10.5.4 Prilosec (omeprazole) 78
10.5.5 Protonix (pantoprazole sodium) 78
10.5.6 Tagamet (cimetidine) 78
10.5.7 Pepcid (famotidine) 78
10.5.8 Zantac (ranitidine hydrochloride) 78
10.5.9 Axid (nizatidine) 78
10.6 Drug Pipeline Analysis 79

11 Global Crohn’s Disease Therapeutics Market 80
11.1 Market Overview 80
11.2 Market Forecasts 81
11.3 Annual Cost of Treatment 82
11.4 Usage Patterns 83
11.4.1 Diseased Population 83
11.4.2 Treatment Seeking Population 84
11.4.3 Diagnosis Population 86
11.4.4 Prescription Population 87
11.4.5 Therapy Usage Patterns 88
11.5 Product Analysis 89
11.5.1 Entocort EC (budenoside) 90
11.5.2 Humira (adalimumab) 90
11.5.3 Tysabri (natalizumab) 90
11.5.4 Remicade (infliximab) 90
11.5.5 Cimzia (cetrolizumab pegol) 91
11.6 Drug Pipeline Analysis 91

12 Global Gastrointestinal Disorder Therapeutics Market: Market Drivers and Restraints 92
12.1 Market Drivers 92
12.1.1 Steady Increase in the Elderly Population 93
12.1.2 Stable Increase in Incidence Rates for Gastrointestinal Disorders 93
12.1.3 Increase in Awareness Levels of Disease Progression and Etiology 93
12.2 Market Restraints 93
12.2.1 Entry of Generics Pose a Serious Problem for Primary Manufacturers 94
12.2.2 Presence of Serious Side Effects for Certain Classes of Therapeutic Drugs 94

13 Global Gastrointestinal Disorder Therapeutics Market : Key Market Trends 95

14 Global Gastrointestinal Disorder Therapeutics Market: Competitive Landscape 96
14.1 Overview 96
14.2 Competitive Profiling 96
14.3 GlaxoSmithKline, Inc 96
14.3.1 Overview 96
14.3.2 Business Description 96
14.4 AstraZeneca 97
14.4.1 Company Overview 97
14.4.2 AZD3355 98
14.5 Pfizer Incorporated 99
14.5.1 Overview 99
14.5.2 Business Description 99
14.6 Novartis Ag 100
14.6.1 Company Overview 100
14.6.2 Business Description 100
14.7 ChemoCentryx Inc. 101
14.7.1 Overview 101
14.7.2 Gastrointestinal Disease Portfolio 101
14.7.3 Crohn’s Disease Product Portfolio 101
14.8 Bristol-Myers Squibb 102
14.8.1 Overview 102
14.8.2 Gastrointestinal Disease Portfolio 102
14.8.3 Crohn’s Disease Product Portfolio 102
14.9 Abbott Laboratories 103
14.9.1 Overview 103
14.9.2 Gastrointestinal Disease Portfolio 103
14.9.3 Crohn’s Disease Product Portfolio 103
14.10 XenoPort, Inc. 104
14.10.1 Company Overview 104
14.10.2 XP19986 104
14.11 Addex Pharmaceuticals 105
14.11.1 Company Overview 105
14.11.2 ADX10059 105
14.12 Vecta Ltd. (Vecta) 106
14.12.1 Company Overview 106
14.12.2 Vecam 106
14.13 Ironwood Pharmaceuticals and Forest Laboratories 107
14.13.1 Company Overview 107
14.13.2 IBS pipeline portfolio 108
14.14 Tioga Pharmaceuticals 109
14.14.1 Company Overview 109
14.14.2 IBS Pipeline Porfolio 109
14.15 Alimentary Health Ltd & P & G 111
14.15.1 Company Overview 111
14.15.2 IBS Pipeline Portfolio 111
14.15.3 Bifantis (Bifidobacterium infantis 35624) 111
14.16 Lexicon 112
14.16.1 Company Overview 112
14.16.2 IBS pipeline portfolio 112
14.16.3 LX-103 112
14.17 Salix Pharmaceuticals 113
14.17.1 Overview 113
14.17.2 Business Description 113
14.17.3 IBS pipeline portfolio 114
Xifaxan (Rifaximin) 114
14.17.4 Ulcerative Colitis pipeline portfolio 115
14.18 Astellas Pharma 115
14.18.1 Overview 115
14.18.2 IBS Pipeline Portfolio 115

15 Gastrointestinal Disorder Therapeutics Market: Pipeline Analysis 118
15.1 Preclinical 119
15.2 Phase I 120
15.3 Pipeline II 122
15.4 Phase III 126
15.5 Promising Drugs under Clinical Development for Crohn’s Disease 129
15.5.1 Myoconda 129
15.5.2 Traficet-EN (CCX282) 129
15.5.3 MLN0002 (vedolizumab) 129
15.5.4 Orencia (abatacept) 129
15.5.5 ABT-874 129
15.5.6 Stelara 129
15.6 Promising Drugs under Clinical Development for Irritable Bowel Syndrome 130
15.6.1 Linaclotide (Linaclotide Acetate) 130
15.6.2 Asimadoline 130
15.6.3 Xifaxan (Rifaximin) 130
15.6.4 Bifantis (Bifidobacterium infantis 35624) 130
15.6.5 LX-103 131
15.6.6 YM060 (Ramosetron hydrochloride) 131
15.7 Promising Drugs under Clinical Development for GERD 131
15.7.1 XP19986 131
15.7.2 AZD3355 131
15.7.3 ADX10059 132
15.7.4 Vecam 132
15.8 Promising Drugs under Clinical Development for Ulcerative Colitis 132
15.8.1 Prograf (Tacrolimus) 132
15.8.2 Vedolizumab 132
15.8.3 Abatacept 132
15.8.4 Adalimumab 133
15.8.5 Golimumab 133

16 Global Gastrointestinal Disorder Therapeutics Market: Strategic Consolidations 134
16.1 Mergers and Acquisitions 134
16.1.1 Overview 134
16.1.2 GlaxoSmithKline Acquires AZ Tika Of AstraZeneca 134
16.1.3 ViroPharma Acquires Lev Pharmaceuticals 134
16.1.4 UCB Acquires Remaining Stake In Schwarz Pharma 134
16.1.5 Teva Pharmaceutical Acquires Bentley Pharmaceuticals 134
16.1.6 Gilead Sciences Acquires Nycomed Limited 135
16.2 Licensing Agreements 135
16.2.1 Overview 135

17 Global Gastrointestinal Disorder Therapeutics Market : Appendix 138
17.1 Market Definitions 138
17.2 Abbreviations 138
17.3 Research Methodology 139
17.3.1 Coverage 139
17.3.2 Secondary Research 139
17.3.3 Primary Research 140
17.3.4 Forecasts 140
17.3.5 Expert Panel Validation 142
17.4 Contact Us 143
17.5 Disclaimer 143

Browse all Pharmaceuticals Market Research Reports at: http://www.reportsandreports.com/market-research/pharmaceuticals/

Browse all GBI Research Market Research Reports at: http://www.reportsandreports.com/Publishers/gbi-research/

Browse all Latest Reports at: http://www.reportsandreports.com/LatestReport.aspx

Related Reports:
U.S. Market for Gastrointestinal Endoscopic Devices 2010 - http://www.reportsandreports.com/market-reports/us-market-for-gastrointestinal-endoscopic-devices-2010/

Cancer Gastrointestinal (Stomach) Cancer Therapy Area Pipeline Report - http://www.reportsandreports.com/market-reports/cancer-gastrointestinal-stomach-cancer-therapy-area-pipeline-re/

Synosia Therapeutics (formerly Synosis Therapeutics)-Company Report - http://www.reportsandreports.com/market-reports/synosia-therapeutics-formerly-synosis-therapeutics-company-repo/

About Us:
Reports and Reports comprises an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts almost all well-known publishers of such reports across the globe. We as a third-party reseller of market research reports employ a number of marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques to drive revenues for our clients. We also provide 24/7 online and offline support service to our customers.

Contact:
Ms. Sunita
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004
Website: http://www.reportsandreports.com/
Blog: http://reportsnreports.wordpress.com/
Blog: http://reportsandreports.blogspot.com/